phase 17
study 16
idelalisib 1
entospletinib 1
pneumonitis 1
limits 1
combination 5
therapy 6
relapsed 10
refractory 9
cll 2
nhl 3
ii 9
belinostat 1
pxd 1
aggressive 3
bcell 23
lymphomas 6
swog 6
s 4
outcomes 7
following 2
watchful 1
waiting 1
stage 3
iiiv 1
follicular 19
lymphoma 69
patients 17
modern 3
era 7
trial 9
evaluate 1
efficacy 1
fostamatinib 3
diffuse 15
large 16
dlbcl 2
using 2
pathology 1
report 3
initial 2
treatment 8
decisions 1
precision 1
medicine 1
approach 1
rchop 3
plus 4
bortezomib 4
induction 2
followed 1
maintenance 3
newly 1
diagnosed 1
mantle 3
cell 8
frontline 1
brentuximab 1
vedotin 1
monotherapy 1
hodgkin 6
aged 1
years 3
older 2
disease 3
characteristics 3
patterns 3
age 2
younger 1
analysis 7
national 5
lymphocare 5
evaluation 2
international 1
prognostic 3
score 2
ips 2
simpler 1
advanced 2
carfilzomib 1
pr 1
vorinostat 1
saha 1
randomized 2
comparing 2
obinutuzumab 1
ga 1
rituximab 15
cd 2
indolent 6
nonhodgkin 14
final 1
gauss 1
inhibition 4
copsignalosome 2
csn 2
deneddylating 2
activity 3
tumor 2
growth 2
doxycycline 2
early 1
relapse 2
cyclophosphamide 2
doxorubicin 2
vincristine 2
prednisone 2
defines 1
high 1
risk 4
death 1
transformed 6
nlcs 1
evolution 1
plasmablastic 1
evades 1
cddirected 1
chimeric 1
antigen 1
receptor 1
t 1
cells 1
intergroup 2
alisertib 2
peripheral 1
tcell 3
mycosis 1
fungoides 1
gray 1
zone 2
features 1
intermediate 1
between 2
classical 2
prognostication 1
among 1
multicenter 2
cohort 1
firstline 2
without 2
chemotherapy 1
advancing 1
radioimmunotherapy 3
future 4
role 2
iii 2
abvd 2
radiotherapy 2
stanford 1
v 1
regimen 2
stages 1
locally 1
extensive 1
bulky 1
mediastinal 1
subset 1
north 1
american 1
e 1
prognosis 2
lymphomarelated 1
mortality 1
elderly 1
united 2
states 2
double 1
hit 1
diagnostic 1
therapeutic 2
challenges 1
low 1
serum 2
vitamin 3
d 3
levels 2
associated 2
inferior 1
survival 1
prospective 1
lysa 1
studies 1
bruton 1
tyrosine 1
kinase 2
inhibitor 2
ibrutinib 2
chemoimmunotherapy 1
chronic 3
lymphocytic 3
leukemia 3
elevated 1
ilr 1
ilra 1
cxcl 1
poor 1
ibritumomab 1
consolidation 2
cycles 1
chop 2
highrisk 1
limitedstage 1
medical 1
history 2
lifestyle 1
family 1
occupational 1
factors 1
sporadic 1
burkitt 3
lymphomaleukemia 1
interlymph 1
subtypes 1
project 1
end 1
lowtumor 1
burden 1
treatmentnaive 1
cdpositive 1
nonrandomised 1
b 5
imexon 1
prooxidant 1
molecule 1
pro 1
novel 3
anticd 1
monoclonal 3
antibody 2
relapsedrefractory 3
correlation 1
clinical 3
responses 1
auc 1
pharmacokinetics 1
iodine 1
tositumomab 1
management 3
marginal 1
comparative 1
factor 1
models 1
based 1
choprituximab 1
versus 2
iodinetositumomab 1
nccn 1
database 1
selective 1
aurora 1
doublehit 1
effectiveness 1
strategies 2
agents 2
syk 2
leads 1
transitional 1
lymphocyte 1
depletion 1
highdose 2
autologous 3
stem 3
transplant 2
late 1
relapses 1
transplantation 2
hdasct 1
hodgkins 4
hl 1
translating 1
findings 1
gene 1
expression 1
analyses 1
practice 1
intraarterial 1
methylprednisolone 1
steroidrefractory 1
acute 1
gastrointestinal 1
hepatic 1
graft 1
host 1
getting 1
heart 1
problem 1
treating 1
answers 1
bendamustine 4
microenvironment 1
macro 1
important 1
prima 1
dose 1
escalation 1
melphalan 1
beam 1
amifostine 1
cytoprotection 1
pcr 1
assays 1
detect 1
blymphocyte 1
clonality 1
formalinfixed 1
paraffinembedded 1
specimens 1
microdissection 1
gemcitabine 2
cytotoxic 1
drugs 1
find 1
primary 1
casecontrol 1
ultraviolet 1
radiation 2
exposure 1
adults 3
pet 3
positive 1
negative 1
peeve 1
disodium 1
has 1
significant 1
review 1
treated 1
intensive 1
chemotherapeutic 1
regimens 1
involved 1
threshold 1
therapies 1
tlr 1
agonist 1
iss 1
emerging 1
salvage 1
timing 1
subsequently 1
undergoing 1
immunotherapy 1
results 2
idiotypespecific 1
response 1
support 1
vaccinal 1
effect 1
symptomatic 1
intracardiac 1
beyond 2
antibodies 2
nonhodgkins 5
old 1
profound 1
hypogammaglobulinemia 1
nonmyeloablative 1
rituximabrefractory 1
singleagent 1
concepts 1
reconstitution 1
recapitulates 1
ontogeny 1
immunomodulatory 1
